Portal de Periódicos da CAPES

Impacts de la nouvelle réglementation du flunitrazépam sur la consommation d’hypnotiques

2003; Elsevier BV; Volume: 58; Issue: 5 Linguagem: Inglês

10.2515/therapie

1958-5578

Caroline Victorri‐Vigneau, Gilles Basset, Michel Bourin, Pascale Jolliet,

Epilepsy research and treatment

The frequent misuse of flunitrazepam has led the French drug agency (AFSSAPS [Agence française de sécurité sanitaire des produits de santé]) to subject this agent to the regulatory regime for drugs known to produce dependency; this drug may now be prescribed for no more than 14 days, is available only on an "ordonnance sécurisée" (prescribing and dispensing subject to stupefacient regulations), and pharmacists must dispense no more than 7 days' supply. We identified, in a French medical-care database, 738 patients who had received at least one flunitrazepam prescription in January 2001, and monitored the hypnotics delivered to this cohort over a period of 8 months. Sixty-nine percent of the patients had replaced flunitrazepam by another hypnotic without any further change. The most surprising result of our survey was the discovery that nearly half of the selected patients stopped using hypnotics during the review period. Although many hypotheses can be offered to account for this phenomenon, it seems that many consumers halted their consumption of flunitrazepam as a result of the new regulatory regime.